• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗前生活质量和功能状态评估能显著预测接受化疗的老年晚期非小细胞肺癌患者的生存期:意大利老年肺癌多中心研究的预后分析

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

作者信息

Maione Paolo, Perrone Francesco, Gallo Ciro, Manzione Luigi, Piantedosi FrancoVito, Barbera Santi, Cigolari Silvio, Rosetti Francesco, Piazza Elena, Robbiati Sergio Federico, Bertetto Oscar, Novello Silvia, Migliorino Maria Rita, Favaretto Adolfo, Spatafora Mario, Ferraù Francesco, Frontini Luciano, Bearz Alessandra, Repetto Lazzaro, Gridelli Cesare, Barletta Emiddio, Barzelloni Maria Luisa, Iaffaioli Rosario Vincenzo, De Maio Ermelinda, Di Maio Massimo, De Feo Gianfranco, Sigoriello Giuseppe, Chiodini Paolo, Cioffi Angela, Guardasole Vincenzo, Angelini Valentina, Rossi Antonio, Bilancia Domenico, Germano Domenico, Lamberti Alfredo, Pontillo Vittorio, Brancaccio Luigi, Renda Francesco, Romano Francesco, Esani Gabriella, Gambaro Anna, Vinante Orazio, Azzarello Giuseppe, Clerici Maurizia, Bollina Roberto, Belloni Paolo, Sannicolò Mirella, Ciuffreda Libero, Parello Giuseppe, Cabiddu Mary, Sacco Cosimo, Sibau Angela, Porcile Gianfranco, Castiglione Federico, Ostellino Oliviero, Monfardini Silvio, Stefani Micaela, Scagliotti Giorgio, Selvaggi Giovanni, De Marinis Filippo, Martelli Olga, Gasparini Giampietro, Morabito Alessandro, Gattuso Domenico, Colucci Giuseppe, Galetta Domenico, Giotta Francesco, Gebbia Vittorio, Borsellino Nicola, Testa Antonio, Malaponte Emilia, Capuano Matteo A, Angiolillo Michele, Sollitto Francesco, Tirelli Umberto, Spazzapan Simona, Adamo Vincenzo, Altavilla Giuseppe, Scimone Antonio, Hopps Maria Raffaella, Tartamella Francesco, Ianniello Giovanni Pietro, Tinessa Vincenza, Failla Giuseppe, Bordonaro Roberto, Gebbia Nicola, Valerio Maria Rosaria, D'Aprile Modesto, Veltri Enzo, Tonato Maurizio, Darwish Samir, Romito Sante, Carrozza Francesco, Barni Sandro, Ardizzoia Antonio, Corradini Giuliana Mara, Pavia Gianfranco, Belli Mario, Colantuoni Giuseppe, Galligioni Enzo, Caffo Orazio, Labianca Roberto, Quadri Antonello, Cortesi Enrico, D'Auria Giuliana, Fava Sergio, Calcagno Anna, Luporini Gino, Locatelli M Cristina, Di Costanzo Francesco, Gasperoni Silvia, Isa Luciano, Candido Paola, Gaion Fernando, Palazzolo Giovanni, Nettis Giuseppe, Annamaria Anselmo, Rinaldi Massimo, Lopez Massimo, Felletti Raffaella, Di Negro Giorgio Bernabò, Rossi Nestore, Calandriello Antonio, Maiorino Luigi, Mattioli Rodolfo, Celano Alfredo, Schiavon Stefania, Illiano Alfonso, Raucci Carlo Alberto, Caruso Michele, Foa Paolo, Tonini Giuseppe, Curcio Carlo, Cazzaniga Marina

机构信息

S Giuseppe Moscati Hospital, Avellino, Italy.

出版信息

J Clin Oncol. 2005 Oct 1;23(28):6865-72. doi: 10.1200/JCO.2005.02.527.

DOI:10.1200/JCO.2005.02.527
PMID:16192578
Abstract

PURPOSE

To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy.

PATIENTS AND METHODS

Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) were used to estimate QoL. ADL was dichotomized as none versus one or more dependency. For IADL and QoL, three categories were defined using first and third quartiles as cut points. Comorbidity was summarized using the Charlson scale. Analysis was performed by Cox model, and stratified by treatment arm.

RESULTS

Better values of baseline QoL (P = .0003) and IADL (P = .04) were significantly associated with better prognosis, whereas ADL (P = .44) and Charlson score (P = .66) had no prognostic value. Performance status 2 (P = .006) and a higher number of metastatic sites (P = .02) also predicted shorter overall survival.

CONCLUSIONS

Pretreatment global QoL and IADL scores, but not ADL and comorbidity, have significant prognostic value for survival of elderly patients with advanced non-small-cell lung cancer who were treated with chemotherapy. Using these scores in clinical practice might improve prognostic prediction for treatment planning.

摘要

目的

研究在接受化疗的老年晚期非小细胞肺癌患者中,功能状态、合并症及生活质量(QoL)的基线评估对总生存期的预后价值。

患者与方法

分析了纳入III期随机多中心意大利老年肺癌研究(MILES)的566例患者的数据。功能状态通过日常生活活动能力(ADL)和工具性日常生活活动能力(IADL)来衡量。采用包含33项内容的检查表评估合并症的存在情况;使用欧洲癌症研究与治疗组织(EORTC)核心问卷QLQ-C30(EORTC QLQ-C30)的第29项和第30项来评估QoL。ADL分为无依赖与有一项或多项依赖。对于IADL和QoL,使用第一和第三四分位数作为切点定义了三个类别。合并症采用Charlson量表进行总结。通过Cox模型进行分析,并按治疗组进行分层。

结果

基线QoL(P = .0003)和IADL(P = .04)的较好值与较好的预后显著相关,而ADL(P = .44)和Charlson评分(P = .66)无预后价值。体能状态2(P = .006)和转移部位数量较多(P = .02)也预示着总生存期较短。

结论

对于接受化疗的老年晚期非小细胞肺癌患者,治疗前的总体QoL和IADL评分具有显著的生存预后价值,而ADL和合并症则没有。在临床实践中使用这些评分可能会改善治疗计划的预后预测。

相似文献

1
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.治疗前生活质量和功能状态评估能显著预测接受化疗的老年晚期非小细胞肺癌患者的生存期:意大利老年肺癌多中心研究的预后分析
J Clin Oncol. 2005 Oct 1;23(28):6865-72. doi: 10.1200/JCO.2005.02.527.
2
Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine.吉西他滨联合长春瑞滨治疗的老年晚期非小细胞肺癌(NSCLC)患者的功能状态、症状及合并症评估
Clin Transl Oncol. 2007 Feb;9(2):99-105. doi: 10.1007/s12094-007-0019-2.
3
Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.长春瑞滨:老年晚期非小细胞肺癌患者应用的综述
Drugs Aging. 2002;19(9):695-721. doi: 10.2165/00002512-200219090-00006.
4
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.老年晚期非小细胞肺癌患者的化疗:意大利老年肺癌多中心研究(MILES)III期随机试验
J Natl Cancer Inst. 2003 Mar 5;95(5):362-72. doi: 10.1093/jnci/95.5.362.
5
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.吉西他滨联合长春瑞滨与顺铂联合长春瑞滨或顺铂联合吉西他滨治疗晚期非小细胞肺癌的比较:意大利GEMVIN研究组和加拿大国家癌症研究所临床试验组的III期试验
J Clin Oncol. 2003 Aug 15;21(16):3025-34. doi: 10.1200/JCO.2003.06.099. Epub 2003 Jul 1.
6
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.吉西他滨及吉西他滨联合长春瑞滨在老年晚期非小细胞肺癌患者中的活性与毒性:来自意大利老年肺癌多中心研究(MILES)随机试验的II期数据
Lung Cancer. 2001 Feb-Mar;31(2-3):277-84. doi: 10.1016/s0169-5002(00)00194-x.
7
Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer.铂类双联疗法作为老年晚期非小细胞肺癌患者的一线治疗方案。
Tumori. 2013 Nov-Dec;99(6):650-5. doi: 10.1177/030089161309900602.
8
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial.在老年晚期非小细胞肺癌患者中,吉西他滨联合长春瑞滨比单用长春瑞滨能产生更好的生存结果。一项意大利南部肿瘤协作组(SICOG)的III期试验。
Lung Cancer. 2001 Dec;34 Suppl 4:S65-9. doi: 10.1016/s0169-5002(01)00392-0.
9
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.老年晚期非小细胞肺癌患者化疗的预后因素
Oncology. 2009;76(5):355-62. doi: 10.1159/000210024. Epub 2009 Mar 25.
10
Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?对于身体状况不佳或老年非小细胞肺癌患者,化疗作为姑息治疗手段是否有作用?
Lung Cancer. 2002 Nov;38 Suppl 2:S45-50. doi: 10.1016/s0169-5002(02)00357-4.

引用本文的文献

1
Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis.患者报告结局作为癌症总生存的预后指标:一项系统评价和荟萃分析
JAMA Oncol. 2025 Sep 11. doi: 10.1001/jamaoncol.2025.3153.
2
Real-World Data on Immune-Checkpoint Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Study.老年晚期非小细胞肺癌患者免疫检查点抑制剂的真实世界数据:一项回顾性研究。
Cancers (Basel). 2025 Jun 29;17(13):2194. doi: 10.3390/cancers17132194.
3
Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study.
S-1单药治疗非小细胞肺癌的真实世界疗效与安全性:一项多中心回顾性队列研究的见解
Clin Med Insights Oncol. 2025 Jul 1;19:11795549251348367. doi: 10.1177/11795549251348367. eCollection 2025.
4
Baseline functioning scales of quality of life (EORTC QLQ-C30) as a predictor of overall survival in patients with lung cancer: a meta-analysis.生活质量基线功能量表(EORTC QLQ-C30)作为肺癌患者总生存期的预测指标:一项荟萃分析。
Support Care Cancer. 2025 Apr 9;33(5):366. doi: 10.1007/s00520-025-09413-w.
5
Recurrent Intracranial Ewing Sarcoma.复发性颅内尤因肉瘤
Ochsner J. 2024 Fall;24(3):213-218. doi: 10.31486/toj.24.0014.
6
Association between Physical Activity and Reduced Mortality in Inoperable Lung Cancer.体力活动与不可切除肺癌患者死亡率降低之间的关联
J Clin Med. 2023 Nov 27;12(23):7346. doi: 10.3390/jcm12237346.
7
Swallowing disorders and mortality in adults with advanced cancer outside the head and neck and upper gastrointestinal tract: a systematic review.晚期头颈部和上消化道外癌症成人的吞咽障碍与死亡率:系统评价。
BMC Palliat Care. 2023 Oct 6;22(1):150. doi: 10.1186/s12904-023-01268-4.
8
Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer.老年评估工具在老年胃肠癌患者中的临床应用
Front Oncol. 2023 May 31;13:1110236. doi: 10.3389/fonc.2023.1110236. eCollection 2023.
9
Lessons learned from organizing International Society of Geriatric Oncology (SIOG) geriatric assessment workshops.从组织国际老年肿瘤学会(SIOG)老年评估研讨会中吸取的经验教训。
J Geriatr Oncol. 2023 Jun;14(5):101528. doi: 10.1016/j.jgo.2023.101528. Epub 2023 May 23.
10
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.免疫检查点抑制剂在老年非小细胞肺癌患者中的疗效和安全性的真实世界数据。
Cancer Med. 2023 May;12(10):11525-11541. doi: 10.1002/cam4.5889. Epub 2023 Mar 31.